查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2117016

固體癌標靶蛋白市場：依適應症、標靶類別、治療方法、作用機制、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Solid Tumors Target Proteins Market, By Indication, By Target Class, By Therapeutic Modality, By Mechanism of Action, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 350 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，固態腫瘤靶向蛋白市場價值將達到 167823 億美元，並將在 2026 年至 2033 年期間以 10.2% 的複合年成長率成長。

固態腫瘤是癌細胞異常增生形成的腫瘤，可發生於各種器官和組織表面或內部，如乳腺、肺、前列腺、結腸、肝臟和胰臟。另一方面，標靶蛋白在惡性細胞中發生失調、擴增、突變或過度表現，促進腫瘤的生長、增殖、存活、侵襲、血管生成和免疫逃脫，因此可作為治療這些疾病的標靶。眾多標靶蛋白包括HER2（ERBB2）、EGFR、VEGF/VEGFR、PD-L1、BRAF、MET、ALK、ROS1、KRAS、PI3K、CDK4/6和PARP。這些分子可利用單株抗體、抗體藥物複合體（ADC）、小分子抑制劑和其他類型的治療藥物進行精準靶向，從而殺死癌細胞或抑制其增殖和轉移能力。因此，固態腫瘤中的標靶蛋白對於開發高效且特異性的惡性腫瘤療法至關重要，這些療法能夠根據每位患者獨特的分子特徵進行個別化治療。

固態腫瘤標靶蛋白市場－市場動態

固態腫瘤發生率的不斷上升正在推動市場成長。

固態腫瘤發生率的上升是固態腫瘤靶向蛋白市場的主要促進因素。肺癌、乳癌、大腸癌、攝護腺癌、肝癌、胃癌和胰臟癌等癌症患者確診數量的增加，預計將推動對分子診斷檢測和標靶治療的需求。世界衛生組織（WHO）和國際癌症研究機構（IARC）的最新報告顯示，全球整體癌症新發病例總數已達約2,060萬例。此外，癌症是第二大死因，每年約奪走1000萬人的生命。世衛組織和國際癌症研究機構預測，到2050年，癌症病例數將激增至每年約3500萬例，這意味著癌症患者數量將顯著增加。

固體癌標靶蛋白市場－市場細分分析：

全球固體癌標靶蛋白市場按適應症、標靶類別、療法、作用機制和地區進行細分。

根據適應症，市場可分為五大類：乳癌、卵巢癌、肺癌、大腸癌和攝護腺癌。由於乳癌率不斷上升，預計固體癌靶向蛋白市場中乳癌領域將出現顯著的銷售成長。例如，根據世界衛生組織估計，到2024年，全球將有約240萬名女性被診斷出罹患乳癌，其中69.4萬人將死於乳癌。乳癌在世界各地所有年齡層的女性中均有發生，從青春期開始，但發病率會隨著年齡增加而增加。

根據治療方法，該市場可分為四大類：抗體藥物複合體(ADC)、CAR-T 受體、單株抗體和小分子藥物。預計抗體藥物複合體(ADC) 細分市場將呈現最高的銷售成長。這一成長主要得益於抗腫瘤抗體藥物複合體偶聯物 (ADC) 的出現。 ADC 透過將抗體與細胞毒性藥物透過連接子偶聯，從而能夠發現腫瘤相關蛋白並進行直接標靶治療。這些藥物能夠選擇性地與癌細胞內的特定蛋白質結合，從而實現藥物向癌細胞的標靶遞送。這使得開發針對多種疾病（包括 HER2 陽性和 TROP-2 陽性癌症）的療法成為可能。 ADC 研發和核准的快速成長預計將提振對目標蛋白的需求，並加速固體癌治療市場的商業化進程。截至 2025 年 2 月，美國食品藥物管理局(FDA) 已批准 10 多種抗體藥物複合體用於各種適應症，顯示 ADC 在癌症治療中的應用率很高。

固體癌標靶蛋白市場－區域分析

預計在整個預測期內，北美仍將是固體癌標靶蛋白市場最大的收入活性化地區，這主要得益於該地區固體癌瘤的高發病率、癌症診斷技術的進步、高度精準的治療策略以及強勁的製藥和生物技術相關活動。根據美國國家癌症研究所 (NCI) 估計，到 2025 年，美國將新增 2,041,910 例癌症病例。美國最常見的癌症類型包括乳癌、攝護腺癌、肺癌和支氣管癌、大腸癌、胰臟癌、腎臟癌和肝癌。

美國固體癌標靶蛋白市場—國家概況

由於美國食品藥物管理局 (FDA) 批准的分子標靶癌症療法數量不斷增加，美國固體癌標靶蛋白市場正在蓬勃發展。 HER2、EGFR、KRAS、BRAF、RET、MET、ALK、ROS1、PD-L1、TROP-2 和 PSMA 等蛋白質和生物標記的商業性價值日益凸顯。 FDA 數據顯示，美國抗癌藥物和生物製藥的研發環境十分穩健。 FDA 血液和腫瘤產品辦公室預計在 2024 年將批准共 89 種抗癌藥物和生物製藥，其中包括 19 種新型分子實體/新型生物製藥以及 34 種現有藥物的新適應症。

目錄

第1章：固體癌標靶蛋白市場概述

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：固體癌標靶蛋白的關鍵市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：固體癌標靶蛋白的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：固體癌標靶蛋白市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：固體癌標靶蛋白的市場趨勢

  • 固體癌標靶蛋白市場佔有率分析（2025年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：固體癌標靶蛋白市場：依適應症分類

  • 概述
    • 基於細分市場的市佔率分析：按適應症
    • 乳癌
    • 卵巢癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
    • 其他

第8章：固體癌標靶蛋白市場：依標靶類別分類

  • 概述
    • 細分市場佔有率分析：依目標類別
    • 查核點抑制劑
      • CTLA-4
      • PD-1
      • PD-L1
    • DNA修復蛋白
    • 生長因子受體
      • EGFR
      • HER2
      • VEGFR
    • 激酶抑制劑
      • 絲胺酸/蘇胺酸激酶抑制劑
      • 蛋白酪氨酸激酶抑制劑
    • 核受體

第9章：固體癌標靶蛋白市場：依治療方式分類

  • 概述
    • 基於細分市場的市佔率分析：依治療方式分類
    • 抗體藥物複合體
    • CAR-T
    • 單株抗體
      • 嵌合體
      • 完全人形
      • 人性化
    • 小分子藥物
    • 其他

第10章：固體癌標靶蛋白市場：依作用機制分類

  • 概述
    • 細分市場佔有率分析：依作用機制分類
    • 變構抑制劑
    • DNA損傷劑
    • 荷爾蒙受體拮抗劑
    • 免疫查核點抑制劑
    • 受體蛋白酪氨酸激酶抑制劑
    • 其他

第11章：固體癌標靶蛋白市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章：主要供應商分析：固體癌標靶蛋白產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • AstraZeneca PLC
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Roche Holding AG/Genentech
    • Pfizer Inc.
    • Eli Lilly and Company
    • Daiichi Sankyo Company, Limited
    • Novartis AG
    • Johnson & Johnson
    • Amgen Inc.
    • AbbVie Inc.
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • GlaxoSmithKline plc
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Exelixis, Inc.
    • BeOne Medicines Ltd.
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7300

Solid Tumors Target Proteins Market size was valued at US$ 1,678.23 Million in 2025, expanding at a CAGR of 10.2% from 2026 to 2033.

Solid tumors are abnormal growths of cancer cells that develop on or in different organs and tissues such as the breast, lungs, prostate, colon, liver and pancreas. In turn, target proteins are dysregulated, amplified, mutated or overexpressed in malignant cells and are contributing to tumor growth, proliferation, survival, invasion, angiogenesis and immune escape and are serving as therapeutic targets for treating such disorders. Some of the many target proteins are HER2 (ERBB2), EGFR, VEGF/VEGFR, PD-L1, BRAF, MET, ALK, ROS1, KRAS, PI3K, CDK4/6, and PARP. These molecules can be precisely targeted using monoclonal antibodies, antibody-drug conjugates, small molecule inhibitors, and other types of therapeutic agents, which will kill cancer cells or hinder the capacity of cancer cells to proliferate and spread. Thus, target proteins in solid tumors are crucial in the development of extremely powerful and specific treatments for malignancies with a personalized view of each patient's unique molecular profile.

Solid Tumors Target Proteins Market- Market Dynamics

Rising prevalence of solid tumors drives market growth

The rising incidence of solid tumors is a significant factor driving the solid tumors target proteins market. Increasing diagnosed cancer patients suffering from lung, breast, colon and rectum, prostate, liver, stomach, and pancreatic cancer and others are expected to propel the demand for molecular diagnostic tests and targeted therapies. As per the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), the overall number of cancer cases worldwide in the latest report reaching around 20.6 million new cases. Moreover, cancer is the second-highest cause of death, leading to nearly 10 million deaths per year. WHO and IARC estimate that the number of cancer incidences will surge to almost 35 million cases per year by 2050, implying a significant rise in the number of cancer patients.

Solid Tumors Target Proteins Market- Segmentation Analysis:

The Global Solid Tumors Target Proteins Market is segmented on the basis of indication, target class, therapeutic modality, mechanism of action, and Region.

The market is divided into five categories based on indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Colorectal Cancer and Prostate Cancer. The Breast Cancer sector is expected to observe significant revenue growth in the Solid Tumors Target Proteins market owing to the increasing incidence of breast cancer. For instance, according to the WHO, in 2024, there were an estimated 2.4 million women diagnosed with breast cancer and 694 000 deaths globally. Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life.

The market is divided into four categories based on therapeutic modality: Antibody Drug Conjugates, Car T, Monoclonal Antibodies and Small Molecules. The Antibody Drug Conjugates segment would witness the highest revenue growth. The growth is attributed to the fact that Antitumor Antibody-Drug Conjugates (ADCs) directly link the discovery of tumor-associated proteins to their targets by using antibodies coupled to cytotoxic drugs via linkers. These drugs have the ability to selectively bind to specific proteins in tumor cells so that drugs can be delivered specifically into the cancerous cells. Therefore, it allows developing treatment for various diseases such as HER2 and TROP-2 positive cancers. The rapid rise in the development and approval of ADCs is projected to boost the demand for target proteins and propel the commercialization of solid-tumor therapeutics market. More than ten antibody drug conjugates have been approved by the U.S Food and Drug Administration (FDA) across indications as of February 2025, suggesting that there is a high adoption rate of ADCs in the treatment of cancer.

Solid Tumors Target Proteins Market- Geographical Insights

North America is expected to remain the leading revenue-generating region for the solid tumors target proteins market during the forecast period, attributed to high prevalence of solid-tumor patients, advanced cancer diagnosis, high-precision treatment strategies, and rising pharmaceutical and biotechnology activities. The U.S. is estimated to witness 2,041,910 new cancer cases in 2025, as reported by the National Cancer Institute of the U.S. Some of the most common types of cancer across the U.S. include breast cancer, prostate cancer, lung, and bronchus cancer, colorectal cancer, pancreatic cancer, kidney cancer, and liver cancer.

US Solid Tumors Target Proteins Market- Country Insights

The U.S market for solid tumors target proteins is witnessing growth due to the rising number of FDA approvals of molecularly targeted therapies against cancer. The commercial value of proteins and biomarkers like HER2, EGFR, KRAS, BRAF, RET, MET, ALK, ROS1, PD-L1, TROP-2, and PSMA is on the rise. According to FDA data, the U.S oncology drug and biologic development environment is robust, as the FDA's Office of Hematology and Oncology Products approved 89 oncology drugs and biologics, including 19 new molecular entities/new biologics and 34 new indications for drugs already on the market in 2024.

Solid Tumors Target Proteins Market- Competitive Landscape:

The solid tumors target proteins market is highly competitive and innovative. The leading pharmaceutical and biotechnology companies are engaged in the discovery and validation of tumor associated proteins, as well as in the development of the corresponding therapeutics; antibody drug-conjugated (ADC) therapeutics, monoclonal antibodies, kinase inhibitors, and companion diagnostics. The companies are focusing on clinically validated tumor-associated targets to increase the likelihood of success during the development process. Thus, the competition is intense, and the key targets are HER2, TROP-2, EGFR, KRAS, ROS1, RET, MET, PD-L1, PSMA, and ESR1. The validation of these tumor-associated proteins facilitates the approval of therapeutics, as well as an expansion into other fields of solid tumors.

Recent Developments:

In June 2026, Johnson & Johnson announced an opportunity inviting global innovators to submit ideas for novel, differentiated technologies with the potential to deliver superior safety and efficacy in the treatment of solid tumors.

In October 2025, AbbVie announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis(TM) (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15 will be featured in multiple presentations.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Roche Holding AG / Genentech
  • Pfizer Inc.
  • Eli Lilly and Company
  • Daiichi Sankyo Company, Limited
  • Novartis AG
  • Johnson & Johnson
  • Amgen Inc.
  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences, Inc.
  • Exelixis, Inc.
  • BeOne Medicines Ltd.
  • Others

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY INDICATION- MARKET ANALYSIS, 2020 - 2033

  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY TARGET CLASS- MARKET ANALYSIS, 2020 - 2033

  • Checkpoint Inhibitors
  • Ctla-4
  • Pd-1
  • Pd-L1
  • Dna Repair Proteins
  • Growth Factor Receptors
  • Egfr
  • Her2
  • Vegfr
  • Kinase Inhibitors
  • Serine Threonine Kinase Inhibitors
  • Tyrosine Kinase Inhibitors
  • Nuclear Receptors

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY THERAPEUTIC MODALITY- MARKET ANALYSIS, 2020 - 2033

  • Antibody Drug Conjugates
  • Car T
  • Monoclonal Antibodies
  • Chimeric
  • Fully Human
  • Humanized
  • Small Molecules

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2020 - 2033

  • Allosteric Inhibitors
  • Dna Damage Agents
  • Hormone Receptor Antagonists
  • Immune Checkpoint Blockers
  • Receptor Tyrosine Kinase Inhibitors

GLOBAL SOLID TUMORS TARGET PROTEINS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Solid Tumors Target Proteins Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Solid Tumors Target Proteins Market Snippet by Indication
    • 2.1.2. Solid Tumors Target Proteins Market Snippet by Target Class
    • 2.1.3. Solid Tumors Target Proteins Market Snippet by Therapeutic Modality
    • 2.1.4. Solid Tumors Target Proteins Market Snippet by Mechanism of Action
    • 2.1.5. Solid Tumors Target Proteins Market Snippet by Country
    • 2.1.6. Solid Tumors Target Proteins Market Snippet by Region
  • 2.2. Competitive Insights

3. Solid Tumors Target Proteins Key Market Trends

  • 3.1. Solid Tumors Target Proteins Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Solid Tumors Target Proteins Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Solid Tumors Target Proteins Market Opportunities
  • 3.4. Solid Tumors Target Proteins Market Future Trends

4. Solid Tumors Target Proteins Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Solid Tumors Target Proteins Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Solid Tumors Target Proteins Market Landscape

  • 6.1. Solid Tumors Target Proteins Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Solid Tumors Target Proteins Market - By Indication

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Indication, 2025 & 2033 (%)
    • 7.1.2. Breast Cancer
    • 7.1.3. Ovarian Cancer
    • 7.1.4. Lung Cancer
    • 7.1.5. Colorectal Cancer
    • 7.1.6. Prostate Cancer
    • 7.1.7. Others

8. Solid Tumors Target Proteins Market - By Target Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Target Class, 2025 & 2033 (%)
    • 8.1.2. Checkpoint Inhibitors
      • 8.1.2.1. Ctla-4
      • 8.1.2.2. Pd-1
      • 8.1.2.3. Pd-L1
    • 8.1.3. Dna Repair Proteins
    • 8.1.4. Growth Factor Receptors
      • 8.1.4.1. Egfr
      • 8.1.4.2. Her2
      • 8.1.4.3. Vegfr
    • 8.1.5. Kinase Inhibitors
      • 8.1.5.1. Serine Threonine Kinase Inhibitors
      • 8.1.5.2. Tyrosine Kinase Inhibitors
    • 8.1.6. Nuclear Receptors

9. Solid Tumors Target Proteins Market - By Therapeutic Modality

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapeutic Modality, 2025 & 2033 (%)
    • 9.1.2. Antibody Drug Conjugates
    • 9.1.3. Car T
    • 9.1.4. Monoclonal Antibodies
      • 9.1.4.1. Chimeric
      • 9.1.4.2. Fully Human
      • 9.1.4.3. Humanized
    • 9.1.5. Small Molecules
    • 9.1.6. Others

10. Solid Tumors Target Proteins Market - By Mechanism of Action

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Mechanism of Action, 2025 & 2033 (%)
    • 10.1.2. Allosteric Inhibitors
    • 10.1.3. Dna Damage Agents
    • 10.1.4. Hormone Receptor Antagonists
    • 10.1.5. Immune Checkpoint Blockers
    • 10.1.6. Receptor Tyrosine Kinase Inhibitors
    • 10.1.7. Others

11. Solid Tumors Target Proteins Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Solid Tumors Target Proteins Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Solid Tumors Target Proteins Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Solid Tumors Target Proteins Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Solid Tumors Target Proteins Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Solid Tumors Target Proteins Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Indication, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Target Class, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Therapeutic Modality, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Solid Tumors Target Proteins Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AstraZeneca PLC
    • 12.2.2. Bristol-Myers Squibb Company
    • 12.2.3. Merck & Co., Inc.
    • 12.2.4. Roche Holding AG / Genentech
    • 12.2.5. Pfizer Inc.
    • 12.2.6. Eli Lilly and Company
    • 12.2.7. Daiichi Sankyo Company, Limited
    • 12.2.8. Novartis AG
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Amgen Inc.
    • 12.2.11. AbbVie Inc.
    • 12.2.12. Bayer AG
    • 12.2.13. Boehringer Ingelheim International GmbH
    • 12.2.14. GlaxoSmithKline plc
    • 12.2.15. Regeneron Pharmaceuticals, Inc.
    • 12.2.16. Sanofi
    • 12.2.17. Takeda Pharmaceutical Company Limited
    • 12.2.18. Gilead Sciences, Inc.
    • 12.2.19. Exelixis, Inc.
    • 12.2.20. BeOne Medicines Ltd.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us